Home » Blog » Cancer Drug Research and Pricing and More

Cancer Drug Research and Pricing and More

IP Blog | Dave Melin | July 16, 2017

In this week’s BioBlog we look at recent happenings in the development and research of cancer drugs, cancer drug price increases, a push by democrats for single-payer healthcare, new Alzheimer disease research, and the ongoing opioid prescription crisis in the US.BioBlog Weekly oncology

Lung, Liver and Stomach Cancers Kill a Million Chinese a Year; Big Pharma Responds

The Wall Street Journal reports that big pharma companies Novartis, Johnson & Johnson, and Sanofi are all working to develop drugs to treat the top three deadliest cancers in China.

FDA Places Clinical Hold on Three Studies Evaluating Pembrolizumab in Multiple Myeloma

Recently Merck announced that the FDA has placed three studies on the use of Keytruda in the treatment of Multiple Myeloma on hold. The move made due to more deaths in two of the studies.

Two Cancer Drug Prices have Already Been Hiked by 8% This Year

Recently cancer drugs have continued to face price increases, added to the list recently were Blincyto and Treanda, increased by 3.9% and 4.5% respectively.

Single-Payer Healthcare Gains Traction with Dems

Recently more Democrats, including potential 2020 candidates, have been showing support toward a single-payer government run healthcare system, but they still lack support from key democratic leaders.

Researchers Discover Atomic Structure of Suspect Alzheimer Proteins

Recently researchers revealed for the first time the atomic structure of the tau protein filaments, a development that should help researchers in the development of new treatments for the disease.

Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015

This CDC report shows that while the prescribing of opioids in the US has slowed from its peak in 2010, the number still remains high and varies greatly by area.

Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *